RxDoctor Payments Data

Vibul Tangpraphaphorn, MD

General Practice · Taft, CANPI 1255514253

Payments from drug & device makers

$3,193in general payments, 2019–2025

Across 43 payments — averaging $74.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$731
  • Pfizer$264
  • Amarin Pharma, Inc.$257
  • Lilly USA, LLC$195
  • Novartis$112
  • plus $324 from 4 others

What the payments were for

  • Food & beverage$3,17699%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,193 in reported general payments places this provider in the 90th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$74,023
Medicare patients
163
Services billed
733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$33,668
MounjaroTirzepatide27$30,123
FarxigaDapagliflozin Propanediol27$25,877
Janumet XrSitagliptin Phos/Metformin Hcl20$20,100
JardianceEmpagliflozin21$19,937
TradjentaLinagliptin13$15,961
Spiriva HandihalerTiotropium Bromide19$13,861
JanuviaSitagliptin Phosphate16$12,685
LinzessLinaclotide16$9,400
Levothyroxine Sodium294$4,265
Atorvastatin Calcium444$3,695
Losartan Potassium309$2,750
Albuterol Sulfate HfaAlbuterol Sulfate85$2,643
Duloxetine Hcl141$2,421
Rosuvastatin Calcium121$1,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$92$35,89834 claims
PfizerEliquis$264$33,66826 claims
Lilly USA, LLCMounjaro$195$30,12327 claims
AstraZenecaFarxiga$1,309$25,87727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 12,963 general practice providers in California.

Other general practice in Taft

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →